...
首页> 外文期刊>International immunopharmacology >Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers.
【24h】

Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers.

机译:在生物标志物的发现和验证中将基因组学应用于器官移植医学。

获取原文
获取原文并翻译 | 示例

摘要

The field of biomarker discovery made a significant leap over the past few decades. As we enter the Era of the Human Genome, thousands of biomarkers can be identified in a relatively high-throughput fashion. While such magnitude and diversity of biomarkers can be seen as a challenge by itself, the field is being moved forward by new advances in bioinformatics and Systems Biology. Because of the life and death nature of end stage organ failure that transplantation treats, the severe donor organ shortage, and the powerful and toxic drug therapies required for the lifetimes of transplant patients, we envision a future for biomarkers as tools to diagnose disease in its early stages, predict prognosis, suggest treatment options and then assist in the implementation of therapies. By harnessing the power of multiple technologies in parallel makes it possible to discover and then validate the next generation of biomarkers for transplantation. We see the road ahead diverge into two paths: one from biomarkers todiagnosis and therapy and the other to a new level of insight into the complex molecular networks that determine when a healthy state becomes diseased and dysfunctional.
机译:在过去的几十年中,生物标志物发现领域取得了重大飞跃。当我们进入人类基因组时代时,可以以相对高通量的方式识别成千上万的生物标记。尽管生物标记物的如此巨大和多样性本身就可被视为挑战,但随着生物信息学和系统生物学的新进展,该领域正在向前发展。由于移植治疗的终末期器官衰竭的生死本质,严重的供体器官短缺以及移植患者一生所需的强大而有毒的药物疗法,我们预见了将生物标志物作为诊断其疾病的工具的未来早期阶段,预测预后,建议治疗方案,然后协助实施治疗。通过并行利用多种技术的力量,可以发现并验证下一代用于移植的生物标志物。我们看到未来的道路分为两条道路:一条从生物标志物到诊断和治疗,另一条对复杂的分子网络有了新的认识,这些分子网络决定了健康状态何时患病和功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号